Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breast implants and autoimmune disease: from signal detection to registry surveillance.

Journal of the National Cancer Institute·2026

Same author

Real-Time Integration of Patient-Reported Outcomes in Breast Cancer Surgery: Feasibility of the BREAST-Q REACT.

Plastic and reconstructive surgery·2026

Same author

Lymphovenous Anastomosis for Treatment of Breast Lymphedema Following Delayed Autologous Reconstruction: A Case Report.

Microsurgery·2026

Same author

Fertility Benefits and Parental Leave Policies across Accreditation Council for Graduate Medical Education (ACGME) Programs with Ob/Gyn Residency Programs.

Fertility and sterility·2026

Same author

Critical role of keratinocytes and protease-activated receptor 2 in secondary lymphedema development.

Clinical and translational medicine·2026

Same author

Longitudinal Trends in wRVU and Reimbursement for Free Flap and Implant-Based Breast Reconstruction: A 13-Year Valuation Analysis.

Plastic and reconstructive surgery·2026

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Th2 cytokines inhibit lymphangiogenesis.

Ira L Savetsky¹, Swapna Ghanta¹, Jason C Gardenier¹

¹The Department of Surgery, Division of Plastic and Reconstructive Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.

|June 4, 2015

Summary

T-helper 2 (Th2) cytokines, including interleukin-4 (IL-4) and interleukin-13 (IL-13), inhibit lymphatic vessel growth. Blocking these cytokines promotes lymphangiogenesis, offering a potential therapeutic strategy.

More Related Videos

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Published on: May 14, 2020

Isolation of Murine Lymph Node Stromal Cells

Isolation of Murine Lymph Node Stromal Cells

Published on: August 19, 2014

Related Experiment Videos

Last Updated: Apr 11, 2026

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Blocking Lymph Flow by Suturing Afferent Lymphatic Vessels in Mice

Published on: May 14, 2020

Isolation of Murine Lymph Node Stromal Cells

Isolation of Murine Lymph Node Stromal Cells

Published on: August 19, 2014

Area of Science:

Vascular biology
Immunology
Cell biology

Background:

Lymphangiogenesis, the growth of new lymphatic vessels, is crucial for wound healing and metastasis.
T-helper 2 (Th2) cytokines are implicated in lymphedema, potentially impairing lymphatic function.
Direct effects of Th2 cytokines on lymphatic endothelial cells (LECs) are not fully understood.

Purpose of the Study:

To investigate the direct impact of Th2 cytokines on LECs.
To determine if Th2 cytokines inhibit lymphangiogenesis.
To explore the therapeutic potential of blocking Th2 cytokines.

Main Methods:

In vitro studies using isolated LECs.
In vivo experiments utilizing the cornea suture model.
Administration of physiologic doses of IL-4 and IL-13.
Inhibition of IL-4 and IL-13 using monoclonal antibodies.

Main Results:

Physiologic doses of IL-4 and IL-13 significantly impaired LEC survival, proliferation, migration, and tubule formation.
Blocking IL-4 and IL-13 in vivo enhanced inflammatory lymphangiogenesis.
Angiogenesis remained unaffected by the inhibition of these Th2 cytokines.

Conclusions:

Th2 cytokines, specifically IL-4 and IL-13, exert potent anti-lymphangiogenic effects on LECs.
Targeting Th2 cytokine pathways offers a novel therapeutic approach to enhance lymphangiogenesis.
Further research into manipulating these pathways could improve treatments for lymphatic disorders.